Predict your next investment

Venture Capital
mediphaseventure.com

See what CB Insights has to offer

Investments

47

Portfolio Exits

15

Funds

3

About Mediphase Venture Partners

Mediphase Venture Partners is a venture capital firm focusing on health care/life sciences companies.

Mediphase Venture Partners Headquarter Location

3 Newton Executive Park Suite 104

Newton, Massachusetts, 02462,

United States

617.332.3408

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Mediphase Venture Partners News

Symphony Technology Group Buys ImpactRx

Apr 18, 2011

Symphony Technology Group Buys ImpactRx April 18, 2011 Private equity firm Symphony Technology Partners has acquired a majority stake in ImpactRx, a developer of a subscription database for pharmaceutical companies. The company, based in Mr. Laurel, N.J., had recently closed a $1.2 million Series E round in January, and was backed by roughly $36 million from investors including Mediphase Venture Partners, 3i Group, Oxford Bioscience Partners and Merck Capital Ventures. Financial terms of the acquisition by Symphony Technology Group were not released. PRESS RELEASE ImpactRx, the pioneer in measuring the impact of promotion on physician prescribing behavior, announced today that Symphony Technology Group (STG), has acquired a majority ownership interest in the Company. STG is a leading private equity firm with a strategic focus on data, analytics and technology-enabled services companies. Merck Capital Ventures (MCV), the venture capital arm of Merck and one of ImpactRx’s existing investors, will maintain its investment in ImpactRx. Under the terms of the acquisition, ImpactRx will operate as an independent STG portfolio company. Current President and CEO, Richard Altus, will continue to lead ImpactRx. Financial terms of the transaction were not disclosed. “Symphony Technology Group’s mission is to invest in companies with a compelling set of assets and capabilities, and solid client relationships, and work closely with management to deliver innovative solutions to customers and increase company growth,” said J.T. Treadwell, Managing Director with STG. “We have nearly a decade of experience partnering with our companies to leverage data, technology, and analytics to deliver breakthrough insight for customers and to expand operations in a cost-effective, timely and thoughtful fashion.” “ImpactRx is a strong company, and a terrific starting point for STG to bring its operations-focused approach to investing in the life sciences industry. We are pleased that Merck Capital Ventures shares our vision as a shareholder committed to ImpactRx’s future.” “We are delighted to be joining forces with Symphony Technology Group”, declared Richard Altus, ImpactRx’s President and CEO. “STG has a very strong track record of working with companies to improve execution through leveraging technologies and best-in-class data analytics in other industries. STG will help ImpactRx to improve as a leader in evaluating and interpreting the drivers of physician behavior, as well as help us expand our reach and scope as a partner to our customers.” Altus stated. “Brand teams are facing increasingly complex challenges; understanding what drives brand performance, through all stages of the life cycle, is more critical today than it ever was,” continued Altus. ‘The acquisition and investment by STG will allow us to further develop our unique capabilities to better respond to our clients’ emerging information and analytical needs. In addition, integrating our proprietary syndicated data set with external secondary and custom data resources, leveraging STG’s vast data modeling and analytics expertise, will enable us to deliver the comprehensive, multi-channel solutions our clients need to grow their businesses in today’s complicated and competitive biopharmaceutical marketplace,” said Altus. STG companies are known for providing high value, high-impact solutions that help customers dramatically improve their performance, productivity and profitability through best-in-class processes and management. Founded in 2000 and headquartered in Mount Laurel, N.J., ImpactRx’s longitudinal panels of high value, iPhone-connected physicians are the exclusive source of continuously-captured promotion and treatment data. Through its proprietary methodology, the Company annually captures one million details and three-million treatment decisions, fueling its unique ImpactData™ industry database. ImpactRx leverages this unprecedented intelligence with custom research and analytics to provide insightful solutions to pharmaceutical marketing and sales decision makers. For more information, visit: www.impactrx.com. About Symphony Technology Group – Symphony Technology Group (STG) is a strategic private equity firm with the mission of investing in and building great software and services companies. In addition to capital, STG provides transformation expertise to enable its companies to deliver maximum value to their clients, to drive growth through innovation, to retain and attract the best talent and to achieve best in class business performance. STG’s current portfolio consists of ten global companies. For more information, visit: www.symphonytg.com. © 2015 Buyouts Insider / Argosy Group LLC

Mediphase Venture Partners Investments

47 Investments

Mediphase Venture Partners has made 47 investments. Their latest investment was in Custom Ink as part of their Option/Warrant on April 4, 2015.

CBI Logo

Mediphase Venture Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/9/2015

Option/Warrant

Custom Ink

$1.15M

Yes

1

8/15/2012

Series C

Relypsa

$80M

No

2

11/2/2010

Unattributed VC

DiscoverX

$8M

No

9/20/2010

Series B

Subscribe to see more

$99M

Subscribe to see more

0

5/19/2010

Series C

Subscribe to see more

$99M

Subscribe to see more

0

Date

4/9/2015

8/15/2012

11/2/2010

9/20/2010

5/19/2010

Round

Option/Warrant

Series C

Unattributed VC

Series B

Series C

Company

Custom Ink

Relypsa

DiscoverX

Subscribe to see more

Subscribe to see more

Amount

$1.15M

$80M

$8M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

0

0

Mediphase Venture Partners Portfolio Exits

15 Portfolio Exits

Mediphase Venture Partners has 15 portfolio exits. Their latest portfolio exit was Custom Ink on May 04, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/4/2019

Acq - Fin

$99M

3

7/31/2017

Acquired

$99M

1

9/24/2014

Acquired

$99M

1

2/13/2014

IPO

Subscribe to see more

$99M

Subscribe to see more

10

11/15/2013

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/4/2019

7/31/2017

9/24/2014

2/13/2014

11/15/2013

Exit

Acq - Fin

Acquired

Acquired

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

1

1

10

10

Mediphase Venture Partners Fund History

3 Fund Histories

Mediphase Venture Partners has 3 funds, including Mediphase Venture Partners II (Select Fund) LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/20/2010

Mediphase Venture Partners II (Select Fund) LP

UNKNOWN

Open

$2M

1

12/31/2003

Mediphase Venture Partners II LP

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2000

EHealth Technology Fund LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

4/20/2010

12/31/2003

12/31/2000

Fund

Mediphase Venture Partners II (Select Fund) LP

Mediphase Venture Partners II LP

EHealth Technology Fund LP

Fund Type

UNKNOWN

Subscribe to see more

Subscribe to see more

Status

Open

Subscribe to see more

Subscribe to see more

Amount

$2M

$99M

$99M

Sources

1

10

10

Mediphase Venture Partners Team

3 Team Members

Mediphase Venture Partners has 3 team members, including current Senior Vice President, Gerald Gallivan.

Name

Work History

Title

Status

Paul A. Howard

Founder

Current

Lawrence G. Miller

Founder

Current

Gerald Gallivan

Senior Vice President

Current

Name

Paul A. Howard

Lawrence G. Miller

Gerald Gallivan

Work History

Title

Founder

Founder

Senior Vice President

Status

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.